Cyclopharm Ltd Asset Resilience Ratio
Cyclopharm Ltd asset resilience ratio. Cyclopharm Ltd (CYC) has an Asset Resilience Ratio of 1.98% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See CYC cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Cyclopharm Ltd (2016–2024)
Asset resilience ratio of Cyclopharm Ltd from 2016 to 2024. This chart shows how Cyclopharm Ltd's Asset Resilience Ratio has changed over time. Read CYC liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Cyclopharm Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Cyclopharm Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$1.23 Million | 1.98% |
| Total Liquid Assets | AU$1.23 Million | 1.98% |
Asset Resilience Insights
- Limited Liquidity: Cyclopharm Ltd maintains only 1.98% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Cyclopharm Ltd Industry Peers by Asset Resilience Ratio
Compare Cyclopharm Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Demant A/S
CO:DEMANT |
Medical Devices | -2.59% |
|
Shanghai Sanyou Medical Co Ltd
SHG:688085 |
Medical Devices | 7.69% |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607 |
Medical Devices | 16.21% |
|
Cleo Diagnostics Ltd
AU:COV |
Medical Devices | 94.64% |
|
Memphasys Ltd
AU:MEM |
Medical Devices | 0.00% |
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Anteris Technologies Global Corp
AU:AVR |
Medical Devices | 33.27% |
|
Polynovo Ltd
AU:PNV |
Medical Devices | 0.04% |
Cyclopharm Ltd Asset Resilience Ratio by Year (2016–2024)
Cyclopharm Ltd asset resilience ratio by year from 2016 to 2024. The table below shows the annual Asset Resilience Ratio data for Cyclopharm Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 1.98% | AU$1.23 Million ≈ $868.47K |
AU$62.13 Million ≈ $43.96 Million |
-24.07pp |
| 2018-12-31 | 26.04% | AU$6.13 Million ≈ $4.34 Million |
AU$23.54 Million ≈ $16.65 Million |
-11.13pp |
| 2017-12-31 | 37.17% | AU$8.69 Million ≈ $6.15 Million |
AU$23.38 Million ≈ $16.54 Million |
+9.20pp |
| 2016-12-31 | 27.97% | AU$4.59 Million ≈ $3.25 Million |
AU$16.41 Million ≈ $11.61 Million |
-- |
About Cyclopharm Ltd
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, the United States, and internationally. The company operates Technegas which offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. It is also involved in the research and development; and distribu… Read more